# US 2004/0081682 A1 · Transdermal system (tds) that contain inhibitors of phosphodiesterase lV

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081682 A1
- Document ID: US20040081682A1
- Status: Published application
- Kind: A1
- Application number: 10/451,225
- Filed: 2003-11-26
- Published: 2004-04-29
- Earliest claimed: 2000-12-21
- Inventors: Clemes Guenther; Ralph Lipp; Fred Windt
- Web page: https://patentgrep.com/patent/US20040081682A1

## CPC

- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 9/7061: {Polyacrylates}
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to a transdermal system that is characterized by a content in a phosphodiesterase IV inhibitor, especially (−) rolipram or (R)-(−)-5-(4-methoxyphenyl-3-propoxy)-5-methyl-2-oxazolidinone.

## Claims

### Claim 1

Transdermal system exhibiting a content of a phosphodiesterase IV inhibitor, characterized in that the phosphodiesterase IV inhibitor is present in a matrix or in a reservoir system and in that the phosphodiesterase IV inhibitor is selected from the group below: (R)-(−)-5-(4-methoxyphenyl-3-propoxy)-5-methyl-2-oxazolidinone, in which the alkyl group contains 1 to 5 carbon atoms, or (R)-(−)-4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone) ((−)-rolipram).

### Claim 2 (depends on 1)

Transdermal system according to claim 1, wherein the phosphodiesterase IV inhibitor is (R)-(−)-5-(4-methoxyphenyl-3-alkoxy)-5-methyl-2-oxazolidinone.

### Claim 3 (depends on 1, 2)

Transdermal system according to claim 1 or 2, wherein the matrix comprises polyacrylate adhesive.

### Claim 4 (depends on 3)

Transdermal system according to claim 3, wherein the polyacrylate adhesive is a copolymer of at least 2 of the following monomers: 2-ethylhexlhexylacrylate, hydroxyethylhexylacrylate, vinyl acetate, and vinyl pyrrolidone.

### Claim 5 (depends on 4)

Transdermal system according to claim 4, wherein the polyacrylate adhesive is a copolymer that consists of 2-ethylhexylacrylate and hydroxyethyl-acrylate or a copolymer of these monomers with vinyl acetate and 2-ethylhexylacrylate-N-vinyl-2-pyrrolidone.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Transdermal system according to one of claims 1 to 5, characterized by a content of phosphodiesterase IV inhibitor of up to 30% by weight in the matrix.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

Transdermal system according to one of claims 1 to 6, wherein the matrix consists of at least one solvent or suspending agent and the dissolved or suspended active ingredient.

### Claim 8 (depends on 7)

Transdermal system according to claim 7, in which the solvent or suspending agent is ethanol or 1,2-propanediol or dimethyl isosorbide or water or mixtures of the above-mentioned substances.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

Transdermal system according to one of claims 1 to 8, wherein the matrix or the solvent or suspending agent comprises at least one crystallization inhibitor.

### Claim 10 (depends on 9)

Transdermal system according to claim 9, wherein the matrix or the solvent or the suspending agent comprises as crystallization inhibitor at least one N-vinyllactam-polymer, such as N-vinyl-1-aza-cycloheptan-2-one homopolymer, N-vinyl-piperidin-2-one homopolymer, polymers of vinyl pyrrolidone such as polyvidone (Kollidon®) or copolymers of vinyl pyrrolidone with vinyl acetate (copovidone) or highly dispersed silicon dioxide (Aevosil).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

Transdermal system according to one of claims 1 to 10, characterized by an additional content of at least one of the following penetration intensifiers: Monovalent or multivalent alcohols such as ethanol, 1,2-propanediol or benzyl alcohol; saturated or unsaturated fatty alcohols with 8 to 18 carbon atoms, such as lauryl alcohol or cetyl alcohol; hydrocarbons such as mineral oil; saturated and unsaturated fatty acids with 8 to 18 carbon atoms, such as stearic acid or oleic acid; fatty acid esters with up to 24 carbon atoms or dicarboxylic acid diesters with up to 24 carbon atoms, such as methyl ester, ethyl ester, isopropyl ester, butyl ester, sec-butyl ester, isobutyl ester, tert-butyl ester or monoglyceric acid ester of acetic acid, caproic acid, lauric acid, myristic acid, stearic acid and palmitic acid, phosphatide derivatives, such as lecithin, terpenes, urea and its derivatives or ethers, such as dimethyl isosorbide and diethylene glycol monoethyl ether.

### Claim 12 (depends on 11)

Transdermal system according to claim 11, characterized by a content of at least one of the following penetration intensifiers: lauryl alcohol, 1,2-propanediol, methyl ester and especially the isopropyl ester of myristic acid or oleic acid, diisopropyl adipate and diisopropyl sebacate, lauric acid and oleic acid, as well as mixtures thereof.
